Form 4: Medifast Director Xian Ming Receives RSU Grant

Director Xian Ming was granted 11,680 cash-settled restricted stock units as part of an annual incentive plan.

Summary

• Director Xian Ming received a grant of 11,680 restricted stock units (RSUs) on May 26, 2026.
• The RSUs are cash-settled, meaning they represent a contingent right to receive the cash equivalent of one share of Medifast common stock per unit upon vesting.
• The grant was issued under the company's 2012 Share Incentive Plan.
• Following this transaction, the reporting person holds a total of 43,822.918 units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• The grant aligns the director's interests with the long-term performance of the company through equity-based compensation.

Negatives

• None identified.

Risks

• The value of the cash-settled RSUs is directly tied to the future market price of Medifast common stock, exposing the holder to market volatility.

Future Outlook

The RSUs are scheduled to vest in full on May 26, 2027, at which point the director will receive the cash equivalent of the underlying common stock.

Industry Context

StockSavvy.ai notes that annual equity grants to directors are standard corporate governance practice to ensure alignment between board members and shareholders, particularly in the consumer health and wellness sector.

Comparison to Industry Standards

• The use of cash-settled RSUs is a common mechanism for director compensation to avoid immediate dilution of existing shareholders while maintaining performance alignment.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation event.

Next Steps

• Vesting of the 11,680 RSUs on May 26, 2027.

Key Dates

Keywords

Medifast, MED, Form 4, Director Compensation, Restricted Stock Units, Insider Transaction